GLP-1 medications like Ozempic affect multiple body systems through these primary mechanisms: Stimulating insulin secretion: When blood glucose levels rise after meals, Ozempic triggers the pancreas to release insulin in a glucose-dependent manner, helping cells absorb sugar from the bloodstream Decreasing glucagon release: The medication suppresses the hormone glucagon, which normally signals the liver to release stored glucose, thereby preventing unnecessary increases in blood sugar Slowing gastric emptying: By delaying how quickly food leaves the stomach and enters the small intestine, Ozempic prolongs feelings of fullness and reduces post-meal blood sugar spikes this same mechanism (which healthcare providers now recognize) has been linked to severe complications in litigation Affecting brain receptors: The medication acts on GLP-1 receptors in brain regions that control appetite and satiety, contributing to substantial weight loss effects that led to its widespread off-label use The FDA approval in December 2017 marked the beginning of what would become one of the fastest-growing pharmaceutical markets in recent history
World Health Organization Western Pacific Region (2016) The Asia-Pacific perspective: redefining obesity and its treatment [Internet] Geneva: World Health Organization
Aggregated, anonymised autonomic data across large patient cohorts would give us something we've never had: a real-time, physiological picture of how these medications affect emotional regulation across different populations, different dosing protocols, different baseline profiles
GLP-1 medications can be a powerful tool for people to improve their health, but theyre not for everyone
In the liraglutide-treated maintenance group, not only was weight regain prevented, but the higher sperm concentration/count achieved after the diet was sustained at 52 weekspubmed.ncbi.nlm.nih.gov
